Treatment of extensive-stage small cell lung carcinoma: current status and future prospects
- PMID: 20044461
- DOI: 10.1183/09031936.00105009
Treatment of extensive-stage small cell lung carcinoma: current status and future prospects
Abstract
Small cell lung cancer (SCLC) is an aggressive lung tumour strongly associated with cigarette smoking, with patients often presenting with metastatic disease at the time of diagnosis. Although SCLC is very chemoradiosensitive and high response rates are obtained with treatment, relapse rates are high and the prognosis remains very poor. In limited-stage SCLC, the overall survival rate has been significantly improved by adding dose-hyperfractionated thoracic radiotherapy and prophylactic cranial irradiation to systemic chemotherapy. In contrast, little progress has been made in the treatment of extensive-stage SCLC (ES-SCLC), apart from the recently documented survival gain by the addition of prophylactic cranial irradiation. First-line therapy in ES-SCLC currently consists of chemotherapy, combining a platinum drug with either etoposide or irinotecan as a possible alternative. New treatments are needed in order to improve the prognosis of ES-SCLC, as median survival with current standard treatment is still only 9-10 months from diagnosis. The present review focuses on the management of ES-SCLC, with special attention to the development of new treatment options.
Similar articles
-
Advances in the treatment of small-cell lung cancer.Semin Respir Crit Care Med. 2011 Feb;32(1):94-101. doi: 10.1055/s-0031-1272873. Epub 2011 Apr 15. Semin Respir Crit Care Med. 2011. PMID: 21500128
-
Dose-intensive therapy for extensive-stage small cell lung cancer and extrapulmonary small cell carcinoma: long-term outcome.Biol Blood Marrow Transplant. 2002;8(6):326-33. Biol Blood Marrow Transplant. 2002. PMID: 12108918 Clinical Trial.
-
Small cell lung cancer: new clinical recommendations and current status of biomarker assessment.Eur J Cancer. 2011 Sep;47 Suppl 3:S272-83. doi: 10.1016/S0959-8049(11)70173-3. Eur J Cancer. 2011. PMID: 21943984 Review.
-
Chemotherapy for small cell lung carcinoma: the Greenlane Hospital experience 1993-1995.N Z Med J. 1998 Nov 27;111(1078):451-2, 453-4. N Z Med J. 1998. PMID: 9891564
-
Extensive-stage small-cell lung cancer: evolution of systemic therapy and future directions.Clin Lung Cancer. 2008 Sep;9(5):262-70. doi: 10.3816/CLC.2008.n.041. Clin Lung Cancer. 2008. PMID: 18953759 Review.
Cited by
-
Early mortality in lung cancer: French prospective multicentre observational study.BMC Pulm Med. 2016 Apr 2;16:45. doi: 10.1186/s12890-016-0205-5. BMC Pulm Med. 2016. PMID: 27039176 Free PMC article.
-
In vivo CaspaseTracker biosensor system for detecting anastasis and non-apoptotic caspase activity.Sci Rep. 2015 Mar 11;5:9015. doi: 10.1038/srep09015. Sci Rep. 2015. PMID: 25757939 Free PMC article.
-
Prognostic factors in extensive-stage small cell lung cancer patients with organ-specific metastasis: unveiling commonalities and disparities.J Cancer Res Clin Oncol. 2024 Feb 2;150(2):74. doi: 10.1007/s00432-024-05621-9. J Cancer Res Clin Oncol. 2024. PMID: 38305793 Free PMC article.
-
Pathological diagnosis and treatment outcome of gastric metastases from small cell lung cancer: A case report.Oncol Lett. 2019 Aug;18(2):1999-2006. doi: 10.3892/ol.2019.10484. Epub 2019 Jun 18. Oncol Lett. 2019. PMID: 31423270 Free PMC article.
-
Identification of DHODH as a therapeutic target in small cell lung cancer.Sci Transl Med. 2019 Nov 6;11(517):eaaw7852. doi: 10.1126/scitranslmed.aaw7852. Sci Transl Med. 2019. PMID: 31694929 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical